The design and synthesis of cysteine protease inhibitors containing isoxazole bearing warheads against Leishmania donovani
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-026-05323-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Gowsia Akhter und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Chemical and Life Sciences, Jamia Hamdard, 110062, New Delhi, India. Hauptthemen laut MEDLINE: Leishmania donovani, Isoxazoles, Cysteine Proteinase Inhibitors, Drug Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Indian Council of Medical Research, SERB, DST.
Abstract (Originalsprache)
Cysteine proteases are critical drug targets for Trypanosomatids, crucial for the host cell invasion, survival and establishing infection. The current therapeutic regimen for leishmaniasis is inadequate, necessitating the search for safer anti-leishmanial agents. A fourteen-member library of new isoxazole derivatives was synthesised using a 1, 3-dipolar cycloaddition approach and then evaluated for antileishmanial activity. Ligands PB, PM and PE were found most effective against intramacrophage amastigotes of Leishmania donovani with EC50 values of 2.42μM, 2.93 μM and 5.19μM, respectively, compared to Amphotericin-B (IC50 2.15 μM). They also inhibited the promastigote stage of the parasite with an EC50 of 9.44 µM, 11.99µM and 14.81 µM, respectively. Mechanistic in silico studies against cysteine protease, followed by in vitro corroboration using Bz-Arg-AMC hydrochloride fluorogenic peptide substrate ascertained the promising potential of PM (IC50 10.34 μM) as a cysteine protease inhibitor. Compounds fared well in the toxicity screen against THP-1 human monocytic cells. Compounds PB, PM and PE emerged as potent hits, and PM with high activity and low toxicity can be further developed into a potent lead molecule (s) to fight Leishmania donovani. The design of isoxazole-based small molecule libraries presents a promising strategy for the development of safer and potent antileishmanial agents targeting cysteine proteases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, School of Chemical and Life Sciences, Jamia Hamdard, 110062, New Delhi, India.
- Department of Molecular Medicine, School of Interdisciplinary Sciences and Technology, Jamia Hamdard, New Delhi, India, 110062.
- Department of Biochemistry, School of Chemical and Life Sciences, Jamia Hamdard, 110062, New Delhi, India.
- ISF College of Pharmacy, Moga, Punjab, 142001, India.
- Department of Chemistry, School of Chemical and Life Sciences, Jamia Hamdard, 110062, New Delhi, India. msalam@jamiahamdard.ac.in.
- Department of Chemistry, Govt. Degree College Baramulla, Khawaja Bagh, J&K 193101, India. mushisjchem@gmail.com.
Förderung
- Indian Council of Medical Research
- SERB, DST
Zitieren
APA
Akhter, G., Beg, M. A., Rehman, S. U., Selvapandiyan, A., Sharma, K., Dhawan, B., Sarfaraz, M., Alam, M. S., Tantray, M. A., & Hamid, H. (2026). The design and synthesis of cysteine protease inhibitors containing isoxazole bearing warheads against Leishmania donovani. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05323-8
Vancouver
Akhter G, Beg MA, Rehman SU, Selvapandiyan A, Sharma K, Dhawan B, et al. The design and synthesis of cysteine protease inhibitors containing isoxazole bearing warheads against Leishmania donovani. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05323-8
BibTeX
@article{Akhter2026,
author = {Akhter, Gowsia and Beg, Mirza A and Rehman, Sayeed Ur and Selvapandiyan, Angamuthu and Sharma, Kalicharan and Dhawan, Bharti and Sarfaraz, Md and Alam, Mohammad Sarwar and Tantray, Mushtaq A and Hamid, Hinna},
title = {The design and synthesis of cysteine protease inhibitors containing isoxazole bearing warheads against Leishmania donovani},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05323-8}
}
EUVIMED